Answers are grounded in this paper and cite their sources.
Case report reveals nonneutralizing autoantibodies against ADAMTS-13 in a patient with thrombotic thrombocytopenic purpura, suggesting alternative mechanisms for enzyme clearance in vivo.
Acquired thrombotic thrombocytopenic purpura (TTP) has been linked to severe deficiency of ADAMTS-13 activity caused by autoantibodies inhibitory to ADAMTS-13. We report data on a patient with confirmed TTP who had severely reduced ADAMTS-13 activity but showed no ADAMTS-13 inhibition in a widely used fluid phase activity assay. With a newly developed enzyme-linked immunosorbent assay, using immobilized recombinant ADAMTS-13, we found high titers of IgM and IgG antibodies that bound to ADAMTS-13, but did not neutralize protease activity. These autoantibodies probably influenced the half-life of ADAMTS-13 or its binding to the endothelial cell surface, thereby compromising ADAMTS-13 activity in vivo. Given that ADAMTS-13 may interact physiologically with various receptors or ligands, the occurrence, distribution, and the epitope mapping of nonneutralizing antibodies will be an important area for future research.
No takes yet. Share an insight, caveat, or question.
Scheiflinger et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: